AlloVir, first to test ElevateBio's model, raises $120M ahead of Phase III

The first disclosed company that will test newly launched ElevateBio's cell and gene therapy model is antiviral treatment developer AlloVir, which revealed the companies' relationship along with a $120 million series B round on Wednesday.

ElevateBio LLC (Cambridge, Mass.) provides its portfolio companies with access to R&D, process development and cGMP manufacturing capabilities in

Read the full 534 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE